At Work With: Martin O'Brien

Share this article:
Martin O'Brien
Martin O'Brien

MARTIN O'BRIEN
Partner, Rosetta

What was your biggest break?
My first agency position out of college was as the assistant to the CEO. Having a front row view proved very advantageous in understanding what a leadership position required.

What's the best and/or worst part of your job?
The best part of my job is coming up with innovative launch strategies. The worst part is losing a client you are heavily invested in.

How long is a typical meeting with clients?
I spend a lot of time with clients in brainstorming or planning meetings, which typically are 2-3 hours long.

Where did you go to college? Did it help you prepare for your career?
I went to Hobart & William Smith Colleges. They focused on critical thinking and writing, both of which have been invaluable in my career.

What was your greatest professional challenge?
Balancing work and family life.

What books are you reading?
I read an article recently about The Revolt of the Masses, a 1929 book by José Ortega y Gasset. The article declared it the smartest thing written about the modern digital age. I am checking it out.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?